You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 11, November 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cutaneous and Subcutaneous Inflammatory Sclerosis Syndromes

John A. Doyle, MB; Suzanne M. Connolly, MD; R. K. Winkelmann, MD, PhD

Arch Dermatol. 1982;118(11):886-890.


Abstract

• Systemic scleroderma and localized scleroderma (morphea) show comparable changes on skin biopsy specimens, and a distinction has often been made on the basis of Raynaud's phenomenon, organ involvement, and laboratory abnormalities characteristically seen in systemic scleroderma. Critical evaluation not only of patients with localized scleroderma but also of those with eosinophilic fasciitis, morphea profunda, and acral pansclerotic morphea has disclosed Raynaud's phenomenon, organ involvement, and laboratory abnormalities typical of systemic scleroderma in a small percentage of patients. Histologically, all five conditions show similar inflammation and sclerosis of the skin, the primary difference being the depth at which these changes occur. These conditions may possibly be related, and the clinical and laboratory differences observed may result from variations in depth, nature, and intensity of the cutaneous and subcutaneous inflammatory sclerosis.

(Arch Dermatol 1982;118:886-890)



Author Affiliations

From the Department of Dermatology, Mayo Clinic and Mayo Foundation, Rochester, Minn.


Footnotes

Accepted for publication Feb 16, 1982.

Reprint requests to Mayo Clinic, Rochester, MN 55905 (Dr Doyle).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of tenosynovitis in linear scleroderma
Hartwright et al.
Rheumatology (Oxford) 2006;45:640-641.
FULL TEXT  

An Unusual Case of Relapsing Myositis In a 12-Year-Old Child
Lucas and Urbach
CLIN PEDIATR 1993;32:438-442.
 

Eosinophilic Fasciitis: Increased Collagen Production and Type I Procollagen Messenger RNA Levels in Fibroblasts Cultured From Involved Skin
Kahari et al.
Arch Dermatol 1990;126:613-617.
ABSTRACT  

Picture of the Month
Iyer et al.
Arch Pediatr Adolesc Med 1989;143:1353-1354.
ABSTRACT  

Linear Scleroderma: Clinical Spectrum, Prognosis, and Laboratory Abnormalities
FALANGA et al.
ANN INTERN MED 1986;104:849-857.
ABSTRACT  

Subcutaneous Sclerosis With Fasciitis and Eosinophilia After Phytonadione Injections
Janin-Mercier et al.
Arch Dermatol 1985;121:1421-1423.
ABSTRACT  

High Titers of Antibodies to Single-Stranded DNA in Linear Scleroderma: Vincent Falanga, MD; Thomas A. Medsger, MD; Morris Reichlin, MD
Arch Dermatol 1985;121:345-347.
ABSTRACT  

Panniculitis in Connective Tissue Disease
Winkelmann
Arch Dermatol 1983;119:336-344.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.